{"filing":{"accession_number":"0001213900-26-064144","cik":"0001711754","ticker":"INMB","company_name":"Inmune Bio, Inc.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"ea0293325-8k_inmune.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026064144/ea0293325-8k_inmune.htm"},"events":[{"id":7518,"run_id":6606,"accession_number":"0001213900-26-064144","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"INmune Bio announced exploratory chi-separation MRI imaging results from the Phase 2 MINDFuL clinical trial of XPro1595 in early Alzheimer's disease patients. While this is a clinical trial result disclosure, it does not fit the standard \"earnings_release\" category (which typically covers quarterly/annual financial results) and appears to be a material clinical development update that would affect investor assessment of the company's pipeline progress. Classified as other_material given the clinical-stage nature of the disclosure and its significance to a biotech company's valuation.","company_name":"Inmune Bio, Inc.","ticker":"INMB","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3646,"accession_number":"0001213900-26-064144","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"INmune Bio announced exploratory chi-separation MRI imaging results from the Phase 2 MINDFuL clinical trial of XPro1595 in early Alzheimer's disease patients. While this is a clinical trial result disclosure, it does not fit the standard \"earnings_release\" category (which typically covers quarterly/annual financial results) and appears to be a material clinical development update that would affect investor assessment of the company's pipeline progress. Classified as other_material given the clinical-stage nature of the disclosure and its significance to a biotech company's valuation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:37:42.423012+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3646,"accession_number":"0001213900-26-064144","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"INmune Bio announced exploratory chi-separation MRI imaging results from the Phase 2 MINDFuL clinical trial of XPro1595 in early Alzheimer's disease patients. While this is a clinical trial result disclosure, it does not fit the standard \"earnings_release\" category (which typically covers quarterly/annual financial results) and appears to be a material clinical development update that would affect investor assessment of the company's pipeline progress. Classified as other_material given the clinical-stage nature of the disclosure and its significance to a biotech company's valuation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:37:42.423012+00:00","company_name":"Inmune Bio, Inc.","ticker":"INMB","filing_date":"2026-06-02"}]}